Risk factors for joint symptoms in the ATAC trial

被引：0
|
作者：
Sestak, I [1 ]
机构：
[1] Wolfson Inst Prevent Med, London, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [1] Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis
    Sestak, Ivana
    Cuzick, Jack
    Sapunar, Francisco
    Eastell, Richard
    Forbes, John F.
    Bianco, Angelo R.
    Buzdar, Aman U.
    LANCET ONCOLOGY, 2008, 9 (09) : 866 - 872
  • [2] Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.
    Buzdar, A. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 15S - 15S
  • [3] Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
    Cuzick, Jack
    Sestak, Ivana
    Cella, David
    Fallowfield, Lesley
    LANCET ONCOLOGY, 2008, 9 (12) : 1143 - 1148
  • [4] The ATAC-trial
    Sainsbury, R
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S81 - S82
  • [5] ATAC trial update
    Del Mastro, L
    Venturini, M
    LANCET, 2005, 365 (9466) : 1225 - 1225
  • [6] Depression in patients with knee osteoarthritis: risk factors and associations with joint symptoms
    Zheng, Shuang
    Tu, Liudan
    Cicuttini, Flavia
    Zhu, Zhaohua
    Han, Weiyu
    Antony, Benny
    Wluka, Anita E.
    Winzenberg, Tania
    Aitken, Dawn
    Blizzard, Leigh
    Jones, Graeme
    Ding, Changhai
    BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)
  • [7] Depression in patients with knee osteoarthritis: risk factors and associations with joint symptoms
    Shuang Zheng
    Liudan Tu
    Flavia Cicuttini
    Zhaohua Zhu
    Weiyu Han
    Benny Antony
    Anita E. Wluka
    Tania Winzenberg
    Dawn Aitken
    Leigh Blizzard
    Graeme Jones
    Changhai Ding
    BMC Musculoskeletal Disorders, 22
  • [8] Risk factors for fracture: 5-year results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S27 - S27
  • [9] Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial
    Cuzick, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S108 - S108
  • [10] Analysis of fracture risk factors from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data.
    Howell, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 18S - 18S
12345